A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorNational Defense Medical Center, Taiwan

About this trial

This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.

Eligibility criteria

Qualifiers

Men or women, ≥ 50 to 85 years of age

At least one 12-lead ECG within 3 months

Disqualifiers

A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5

A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy

Prior heart, lung, or heart-lung transplants

Any systolic pulmonary artery pressure >50 mmHg by echocardiography before

Trial design

Treatments tested in this trial

  • AI-ECG Guidance

Treatment groups

8,666 Participants
are divided into 2 treatment groups